Arsenic, a toxicant in foods and environmental media such as soil and water, is the 20th most abundant element in the earth crust (Mandal and Suzuki, 2002). Because 140 million people worldwide are at risk of exposure to excessive levels of naturally occurring arsenic in well water and groundwater (Hall et al., 2009), exposure of arsenic in drinking water is a serious public health problem. Many epidemiological studies have shown that arsenic exposure is linked to not only cancers but also vascular diseases such as atherosclerosis, hypertension, and Blackfoot disease (Stea et al., 2014).

Nitric oxide (NO) in endothelial cells (EC) is a key molecule with multiple functions, including vasodilation and many antiatherogenic properties. The production of NO is mainly regulated by endothelial NO synthase (eNOS) and therefore its dysregulation is thought to contribute to the pathogenesis of vasodilation-related diseases such as atherosclerosis and hypertension (Isenovic et al., 2011). It is known that eNOS is mainly controlled at the level of its phosphorylation (Rafikov et al., 2014).

Arsenic Acutely Decreases Nitric Oxide Production via the ROS—Protein Phosphatase 1—Endothelial Nitric Oxide Synthase-Thr497 Signaling Cascade

Jungwon Seo, Jee Young Lee, Min-Sun Sung, Catherine Jeonghae Byun, Du-Hyong Cho, Hyeon-Ju Lee, Jung-Hyun Park, Ho-Seong Cho, Sung-Jin Cho and Inho Jo

Department of Molecular Medicine, School of Medicine, Ewha Womans University, Seoul 158-710, Institute of Pharmaceutical Research and Development, College of Pharmacy, Wonkwang University, Iksan 570-749, Department of Pharmacology, School of Medicine, Eulji University, Daejeon 301-768, Biosafety Research Institute and College of Veterinary Medicine, Chonbuk National University, Jeonju 561-756, Department of Biology, College of Natural Sciences, Chungbuk National University, Cheongju 362-763, Republic of Korea

Abstract

Chronic (>24 h) exposure of arsenite, an environmental toxicant, has shown the decreased nitric oxide (NO) production in endothelial cells (EC) by decreasing endothelial NO synthase (eNOS) expression and/or its phosphorylation at serine 1179 (eNOS-Ser1179 in bovine sequence), which is associated with increased risk of vascular diseases. Here, we investigated the acute (<24 h) effect of arsenite on NO production using bovine aortic EC (BAEC). Arsenite acutely increased the phosphorylation of eNOS-Thr497, but not of eNOS-Ser116 or eNOS-Ser1179, which was accompanied by decreased NO production. The level of eNOS expression was unaltered under this condition. Treatment with arsenite also induced reactive oxygen species (ROS) production, and pretreatment with a ROS scavenger N-acetyl-L-cysteine (NAC) completely reversed the observed effect of arsenite on eNOS-Thr497 phosphorylation. Although protein kinase C (PKC) and protein phosphatase 1 (PP1) were reported to be involved in eNOS-Thr497 phosphorylation, treatment with PKC inhibitor, Ro318425, and overexpression of various PKC isoforms did not affect the arsenite-stimulated eNOS-Thr497 phosphorylation. In contrast, treatment with PP1 inhibitor, calyculin A, mimicked the observed effect of arsenite on eNOS-Thr497 phosphorylation. Lastly, we found decreased cellular PP1 activity in arsenite-treated cells, which was reversed by NAC. Overall, our study demonstrates firstly that arsenite acutely decreases NO production at least in part by increasing eNOS-Thr497 phosphorylation via ROS-PP1 signaling pathway, which provide the molecular mechanism underlying arsenite-induced increase in vascular disease.

Key Words: Arsenite, Vascular disease, Nitric oxide, Endothelial nitric oxide synthase, Reactive oxygen species, Protein phosphatase 1

INTRODUCTION

Arsenic, a toxicant in foods and environmental media such as soil and water, is the 20th most abundant element in the earth crust (Mandal and Suzuki, 2002). Because 140 million people worldwide are at risk of exposure to excessive levels of naturally occurring arsenic in well water and groundwater (Hall et al., 2009), exposure of arsenic in drinking water is a serious public health problem. Many epidemiological studies have shown that arsenic exposure is linked to not only cancers but also vascular diseases such as atherosclerosis, hypertension, and Blackfoot disease (Stea et al., 2014).

Nitric oxide (NO) in endothelial cells (EC) is a key molecule with multiple functions, including vasodilation and many antiatherogenic properties. The production of NO is mainly regulated by endothelial NO synthase (eNOS) and therefore its dysregulation is thought to contribute to the pathogenesis of vasodilation-related diseases such as atherosclerosis and hypertension (Isenovic et al., 2011). It is known that eNOS is mainly controlled at the level of its phosphorylation (Rafikov et al., 2014).
Several specific sites of phosphorylation have been identified among which, eNOS at serine 1179 (eNOS-Ser<sup>1179</sup>) in bovine sequence has been the most studied. The phosphorylation of eNOS-Ser<sup>1179</sup> increases NO production, which is mediated by several specific protein kinases, including Akt, AMP-activated protein kinase (AMPK), calmodulin-dependent kinase II (CaMKII), protein kinase A (PKA), and check point kinase 1 (Park et al., 2011; Rafikov et al., 2011). In addition to kinases, protein phosphatase 2A (PP2A) is also reported to be involved in the level of eNOS-Ser<sup>1179</sup> phosphorylation (Park et al., 2013). Conversely, the phosphorylation of eNOS-Thr<sup>497</sup> decreases eNOS activity, which is mediated by AMPK (Chen et al., 1999), PKC (Fleming et al., 2001; Matsubara et al., 2003) or ROCK (Watts and Motley, 2009). This site is also dephosphorylated by PP1 and PP2A, which results in an increase in NO production (Michell et al., 2001; Greif et al., 2002). Like eNOS-Thr<sup>497</sup> phosphorylation, the phosphorylation of eNOS-Ser<sup>1179</sup> decreases eNOS activity and NO production. In basal EC, we reported that the phosphorylation of eNOS-Thr<sup>186</sup> is mediated by cyclin-dependent kinase 5 (CDK5) and c-Jun N-terminal kinase 2 (Cho et al., 2010; Park et al., 2012). Very recently, we further reported that the inhibition of CDK5-mediated eNOS-Ser<sup>1179</sup> phosphorylation is a major mechanism by which valproic acid increases NO production and that this process was mediated by SH2 domain-containing protein tyrosine phosphatase 1 (Cho et al., 2014).

Decreased NO bioavailability in endothelium is implicated in the pathology of arsenic poisoning (Kumagai and Pi, 2004). For example, studies in an endemic area of chronic arsenic poisoning in inner Mongolia (Pi et al., 2000) and in arsenite-administered rats (Lee et al., 2003) revealed that serum concentration of stable NO metabolites was lower in arsenic-exposed subjects than controls. In EC, the treatment with arsenite was also reported to suppress eNOS activity (Pi et al., 2000; Lee et al., 2003) and NO production (Barchowsky et al., 1999), although there are several conflicting reports showing that arsenite increases NO production (Liu and Jan, 2000; Kao et al., 2003). In this study, we reexamined the effect of arsenite on NO production and its underlying molecular mechanism, in particular its acute effect, because so far most studies have evaluated the effect of chronic arsenite exposure on NO production. Our result showed that arsenite acutely decreased NO production at least in part by phosphorylating eNOS-Thr<sup>186</sup> via reactive oxygen species (ROS)-stimulated inhibition of PP1 activity.

**MATERIALS AND METHODS**

**Materials**

Sodium arsenite (NaAsO<sub>2</sub>, used as arsenite) was purchased from VWR international (West Chester, PA, USA). Calyculin A, okadaic acid and Ro318425 were obtained from Calbiochem (Nottingham, UK), N-Acetyl-L-cysteine (NAC) and 2′,7′-dichlorofluorescin diacetate (DCFH-DA) were purchased from Sigma (St. Louis, MO, USA). Antibodies against eNOS, p-eNOS-Ser<sup>1179</sup>, p-eNOS-Thr<sup>497</sup> and p-eNOS-Ser<sup>116</sup> were obtained from BD Transduction Laboratories (Lexington, KY, USA) and Upstate (Lake Placid, NY, USA), respectively. Antibodies against PP1α, β-actin, and all corresponding secondary antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA). Lipofectamine 2000, Minimal essential medium (MEM), Dulbecco’s phosphate-buffered saline (DPBS), newborn calf serum (NCS), penicillin-streptomycin antibiotics, L-glutamine, trypsin-EDTA solution, and plasticware for cell culture were obtained from Gibco-BRL (Gaithersberg, MD, USA). All other chemicals were of the purest analytical grade.

**Cell culture, drug treatments, and transfection**

Bovine aortic EC (BAEC) were isolated and cultured exactly as described previously (Kim et al., 1999) and maintained in MEM supplemented with 5% NCS at 37°C under 5% CO<sub>2</sub> in air. EC were confirmed by their typical cobblestone configuration when viewed by light microscopy and by a positive indirect immunofluorescence test for von Willebrand factor VIII. The cells between passages 5 and 10 were used for all experiments. When BAEC were grown to confluence, the cells were further maintained for the indicated times in MEM with 5% NCS containing various concentrations of sodium arsenite. In some experiments, the cells were treated with various chemicals for 0.5 h before arsenite treatment. Transfection was done exactly as described (Cho et al., 2010). Briefly, pcDNA3.1 mammalian expression vector containing cDNA (each 3 µg) encoding haemagglutinin A (HA)-tagged dominant negative (DN)-PKC (a kind gift from Professor Jae-Won Soh, Department of Chemistry, Inha University, Korea) was transfected into the cells grown to 70% confluence in 60 mm dishes using Lipofectamine 2000, according to the manufacturer’s instructions. For control, equal amounts of pcDNA3.1 vector were also transfected.

**Western blot analysis**

For Western blot analysis, BAEC treated with sodium arsenite in the absence or presence of various chemicals were washed with ice-cold DPBS and lysed in lysis buffer (20 mM Tris-HCl at pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA) containing 1×Protease Inhibitor CocktailTM (Roche Molecular Biochemicals, Indianapolis, IN) and 1× Phosphatase Inhibitor Cocktail 2 (Sigma). The protein concentrations were determined using a BCA protein assay kit (Sigma). Equal quantities of protein (20 µg) were separated on sodium dodecyl sulfate polyacrylamide gel under reducing conditions and then electrophoretically transferred onto nitrocellulose membranes. The blots were then probed with the appropriate antibodies, followed by the corresponding secondary antibodies, and finally developed using ECL reagents (Amersham Biosciences, Arlington Heights, IL, USA).

**Measurement of NO release**

NO released by BAEC was measured as nitrite (a stable metabolite of NO) concentration in cell culture supernatant as described (Cho et al., 2004). The culture medium in 100 mm dish was changed to 1 ml of Kreb’s buffer (pH 7.4; 118 mM NaCl, 4.6 mM KCl, 27.2 mM NaHCO<sub>3</sub>, 1.2 mM MgSO<sub>4</sub>, 2.5 mM CaCl<sub>2</sub>, 1.2 mM KH<sub>2</sub>PO<sub>4</sub> and 11.1 mM glucose) and incubate for 1 h at 37°C. Two hundred µl of each supernatant was then carefully transferred into a 96-well plate, with the subsequent addition of 100 µl of Griess reagent (50 µl of 1% sulfanilamide containing 5% phosphoric acid and 50 µl of 0.1% N-(1-naphthyl) ethylenediamine). After color development at room temperature for 15 min, absorbance was measured on a microplate reader at a 530 nm wavelength.
Fig. 1. Arsenite increases phosphorylation of eNOS-Thr^{497} and decreases NO production in BAEC. BAEC were treated with (A) 30 μM sodium arsenite (NaAsO\textsubscript{2}) for shorter times (4, 8, or 24 h), (B) for longer times (up to 36 h), or (C) with various doses of sodium arsenite (10, 20, or 30 μM) for 4 h (C). Control cells (0 h or 0 μM) were treated with vehicle (H\textsubscript{2}O) only. The cells were lysed, and the amounts of phosphorylated eNOS (p-eNOS) at multiple sites were measured by Western blot analysis using antibodies specific for eNOS phosphorylated at Ser^{116} (p-eNOS-Ser\textsuperscript{116}), p-eNOS-Thr\textsuperscript{497}, or p-eNOS-Ser\textsuperscript{1179}. The blots shown are representative of at least three experiments. Densitometry was used to quantify p-eNOS-Ser\textsuperscript{116}, p-eNOS-Thr\textsuperscript{497}, or p-eNOS-Ser\textsuperscript{1179} relative to the total protein bands, and the graphs show the mean fold alterations above or below control (± S.D.) (n=3). Differences were statistically significant at *p<0.05 and **p<0.01. (D) After BAEC were treated with 30 μM sodium arsenite for the indicated times, NO released by the cells was measured by the Griess method. Each bar represents the mean NO production (after normalization to total cellular protein) as fold decreases below control (vehicle) (± S.D.) (n=3). Differences were statistically significant at *p<0.05 and **p<0.01.
that in the control. ROS production was determined by comparing the excitation wavelength of 488 nm and an emission wavelength of 530 nm. ROS production was quantified with FACSCalibur (BD Biosciences) by measuring DCF fluorescence intensity from the control experiment.

**Cell viability assay**

Cell viability assay was carried out as described (Park et al., 2011) using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) with minor modifications. BAEC grown in 96-well culture plates were treated with 30 μM sodium arsenite for various times (up to 36 h). After treatments, cells were incubated with 5 mg/ml MTT and further incubated for 2 h at 37°C. Dimethyl sulfoxide (DMSO) (200 μL) was added to the cells, incubated for 10 min more and absorbance read at 570 nm using a 96-well microtiter plate reader.

**Measurement of intracellular reactive oxygen species (ROS) formation**

Production of ROS was measured using an oxidation-sensitive fluorescent probe DCFH-DA, based on the ROS-dependent oxidation of DCFH-DA to 2',7'-dichlorofluorescein (DCF), as described (Lee et al., 2007). BAEC treated with 30 μM sodium arsenite for various times were detached with trypsin-EDTA, washed with PBS, and then treated with 2 μM DCFH-DA in PBS at 37°C for 15 min. After wash twice with PBS, cells were immediately monitored with FACSCalibur flow cytometry (BD Biosciences, San Jose, CA, USA) at an excitation wavelength of 488 nm and an emission wavelength of 525 nm. ROS production was determined by comparing the changes in fluorescence intensity in drug-treated cells with that in the control.

**Measurement of PP1 activity assay**

PP1 activity assay was carried out using ProFluor® Ser/Thr PPase Assay kit (Promega, Madison, WI, USA) according to the manufacturer’s instruction. Briefly, cells were treated with 30 μM sodium arsenite or vehicle for 4 h, and lysed with lysis buffer (20 mM Tris-Cl at pH 7.4, 132 mM NaCl, 1% Triton X-100) containing 1×Protease Inhibitor Cocktail™ (Roche Molecular Biochemicals) and 1×PMSF. In some experiments, cells were also preincubated with 10 mM NAC for 0.5 h before sodium arsenite treatment. After treatments, cell lysates were centrifuged at 12,000 g for 10 min, and the supernatant was collected. Protein concentration was determined using the BCA method (Sigma), and equal amount of protein in supernatant (100 μg) was immunoprecipitated using 4 μl of antibody against PP1 or 4 μl of normal rabbit IgG for the control experiment. The immunoprecipitates were washed twice with lysis buffer lacking both protease inhibitor and phosphatase inhibitor, and twice more with 1× the reaction buffer B. Finally, the purified PP1 immunoprecipitates were resuspended in 25 μl of 1× reaction buffer B containing 2 mM MgCl2 and 0.4 mM MnCl2. Reaction was then started by adding 25 μl of the peptide solution containing 10 μM TTPase R110 substrate to the samples. The reaction samples were incubated for 10 min at room temperature and followed by further incubation with the protease solution for 90 min. The reaction was then stopped by adding 25 μl of the stabilizer solution containing 3 μM o-phenylenediamine to the reaction mixture. The cellular PP1 activity was quantified with FACSCalibur (BD Biosciences) by measuring the fluorescence intensity at an excitation wavelength of 485 nm and an emission wavelength of 530 nm and normalized to the fluorescence intensity from the control experiment.

**Statistical analysis**

All results are expressed as means ± standard deviation (S.D.) with n indicating the number of experiments. Statistical significance of difference was determined using Student’s t test for paired data. A value of p<0.05 was considered significant.
RESULTS

Arsenite acutely increases eNOS-Thr497 phosphorylation and decreases NO production

Because chronic (>24 h) exposure of arsenite has shown the increased vascular dysfunction mainly by decreasing eNOS-Ser1179 phosphorylation-mediated NO production, we asked whether acute exposure of arsenite also decreases NO production via decreased eNOS-Ser1179 phosphorylation. As shown in Fig. 1A, however, arsenite (30 μM) acutely (as...
early as 4 h) increased eNOS-Thr497 phosphorylation, but not of eNOS-Ser1179 phosphorylation, although its longer (at 24 h) exposure considerably decreased eNOS-Ser1179 phosphorylation. No alterations in eNOS-Ser116 phosphorylation and eNOS expression were found under these conditions. However, longer (36 h) exposure of arsenite significantly decreased eNOS expression (Fig. 1B), which was accompanied by significantly decreased cell viability (data not shown). We also found that arsenite acutely increased eNOS-Thr497 phosphorylation in a dose-dependent manner (Fig. 1C). Consistent with phosphorylation status of eNOS-Thr497, arsenite decreased NO production in a time-dependent manner (Fig. 1D). Because a significant increase in eNOS-Thr497 phosphorylation was found in BAEC acutely exposed to arsenite, all subsequent experiments were accomplished with 30 μM arsenite treatment for 4 h, unless otherwise specifically stated.

**Arsenite increases ROS production and NAC reverses the arsenite-stimulated increase in eNOS-Thr497 phosphorylation in BAEC**

Several studies have demonstrated that arsenite generates ROS that leads to alteration in the activity of proteins; for example, arsenite increases ROS, resulting in increased expression or secretion of vascular endothelial growth factor (VEGF) in cancer cells and brain microvascular pericytes, respectively (Gao et al., 2004; Park et al., 2009). Therefore, we first evaluated whether arsenite induced ROS production in BAEC. As shown in Fig 2A, arsenite acutely (as early as 0.5 h) increased ROS production by ~1.75 fold and this increase was maintained up to 4 h. Next, we tested whether increased ROS affected eNOS-Thr497 phosphorylation. Pretreatment with antioxidant NAC (10 mM) for 0.5 h almost completely reversed the arsenite-induced increase in eNOS-Thr497 phosphorylation (Fig. 2B), suggesting that ROS mediates the observed effect by arsenite.

**PKC is not involved in the arsenite-stimulated increase in eNOS-Thr497 phosphorylation**

PKC has been reported to phosphorylate eNOS-Thr497 in *in vitro* phosphorylation experiment (Matsubara et al., 2003) and in cultured EC (Fleming et al., 2001; Matsubara et al., 2003). These data, together with previous report that ROS had also been to be capable of activating PKC through oxidation of its N-terminal regulatory domain (Cosentino-Gomes et al., 2012), prompted us to examine whether PKC mediates the arsenite-induced increase in eNOS-Thr497 phosphorylation. Experiment evaluating the effect of PKC-specific inhibitor, Ro318425, however, did not alter the arsenite-stimulated eNOS-Thr497 phosphorylation (Fig. 3A). To further clarify these data, we transfected dominant-negative (DN) PKC isoforms, αI, II, III, δ, ε, and ζ, into BAEC. In accordance with the result from PKC inhibitor experiment, overexpression of DN-PKC genes did not reverse the increased eNOS-Thr497 phosphorylation by arsenite (Fig. 3B), which suggests that PKC is not involved in the arsenite-stimulated increase in eNOS-Thr497 phosphorylation.

**Calyculin A, but not okadaic acid, mimics the stimulatory effect of arsenite on eNOS-Thr497 phosphorylation**

PP1 and PP2A have been also implicated in agonist-induced eNOS-Thr497 dephosphorylation (Michell et al., 2001; Greif et al., 2002). To elucidate whether PP1 or PP2A is associated with the arsenite-induced increase in eNOS-Thr497 phosphorylation, we first treated BAEC with okadaic acid (2.5 or 5 nM) at a concentration known to specifically inhibit PP2A activity. As shown in Fig. 3C, no alteration eNOS-Thr497 phosphorylation was found in okadaic acid-treated cells, indicating no evidence for involvement of PP2A under our condition. In contrast, treatment with calyculin A, a specific PP1 inhibitor, dramatically increased eNOS-Thr497 phosphorylation in a dose-dependent manner (Fig. 3D), mimicking the observed effect of arsenite on eNOS-Thr497 phosphorylation. However, the simultaneous treatment with calyculin A and arsenite led to neither additive nor synergistic effect on the phosphorylation of eNOS-Thr497 when compared with treatment with calyculin A alone (Fig. 3E), implying that arsenite and calyculin A increased eNOS-Thr497 phosphorylation through the same signaling axis for PP1 activity inhibition. All these data suggest that PP1 may be involved in the arsenite-stimulated increase...
in eNOS-Thr⁴⁹⁷ phosphorylation.

**Arsenite inhibits PP1 that is reversed by NAC**

To elucidate the molecular mechanism by which arsenite acutely increases PP1-mediated eNOS-Thr⁴⁹⁷ phosphorylation, we investigated whether arsenite indeed decreases the protein level and/or the activity of PP1 in BAEC. Although it was reported that arsenite treatment decreased the level of PP1α expression in human lymphoblastoid cells (Tapio et al., 2005), we failed to decrease in the level of PP1α expression in arsenite-treated BAEC (Fig. 4A). Instead, arsenite significantly decreased PP1 activity by ~15% (Fig. 4B). Furthermore, the arsenite-induced decrease in PP1 activity was almost completely recovered by the pretreatment of NAC, suggesting that ROS mediates decreased PP1 activity by arsenite.

**DISCUSSION**

Epidemiology studies showed that arsenic exposure is associated with increased risk of cardiovascular diseases including hypertension and peripheral vascular diseases (Stea et al., 2014). Although decreased NO bioavailability may be one important reason for arsenic-derived increase in these diseases, its detailed mechanism has not been defined. In this study, we demonstrate that arsenite attenuates NO production in BAEC via a coordinated interplay of two phosphorylation sites on eNOS: acute (~24 h) exposure of arsenite decreases NO production by increasing eNOS-Thr⁴⁹⁷ phosphorylation. In contrast, chronic (>24 h) arsenite exposure further decreases NO production via a combination of increased eNOS-Thr⁴⁹⁷ phosphorylation and decreased eNOS-Ser¹¹⁷⁹ phosphorylation, together with decreased eNOS expression. Lastly, our data also show that ROS-induced inhibition of PP1 activity provides the mechanism by which arsenite acutely decreases NO production via an increased eNOS-Thr⁴⁹⁷ phosphorylation.

One of the most important findings in this study is that eNOS-Thr⁴⁹⁷ phosphorylation mediates the acute effect of NO production. Although previous studies also showed that arsenite decreased NO production and eNOS activity in EC, these studies mostly focused on handling eNOS-Ser¹¹⁷⁹ phosphorylation and/or eNOS expression to explore its underlying mechanism (Tsou et al., 2005). Our study also showed decreases in eNOS-Ser¹¹⁷⁹ phosphorylation and eNOS expression particularly in chronic exposure of arsenite, the condition which most of previous studies have adopted. In this regard, our findings bring an important aspect in that dynamic regulation of eNOS activity via its multiple phosphorylation sites determines the net effect of certain agonists on NO production. Several studies have supported this concept showing that there was the coordinated regulation between eNOS-Ser¹¹⁷⁹ phosphorylation and eNOS-Thr⁴⁹⁷ dephosphorylation when EC were stimulated by VEGF (Michell et al., 2001), bradykinin (Harris et al., 2001), or H₂O₂ (Thomas et al., 2002).

It is well accepted that oxidative stress modulating cell signaling pathway has been known as one of the main causes of arsenic-induced toxicity. For example, arsenite increases expression of VEGF and hypoxia-inducible factor 1α via a ROS production in EC (Kao et al., 2003; Kamat et al., 2005) and cancer cells (Gao et al., 2004; Kamat et al., 2005). Concurrently, we reported that arsenite increased VEGF secretion in a ROS-dependent manner in microvascular pericytes. Based on this study, other important findings are shown that ROS induced by arsenite can cause vascular dysfunction via decreased NO production and that eNOS-Thr⁴⁹⁷ phosphorylation is likely to be one of targets of ROS induced by arsenic toxicity. Whether decreased eNOS-Ser¹¹⁷⁹ phosphorylation by chronic exposure of arsenite is also ROS-dependent under our condition warrants further investigations.

Previously, PP1, PP2A or PKC was reported to be involved in alteration in eNOS-Thr⁴⁹⁷ phosphorylation (Fleming et al., 2001; Michell et al., 2001). Based on these data, together with previous finding that NADPH oxidase-derived ROS showed oxidative activation of PKCα in EC, which is essential for vascular cell adherence molecule-1-dependent transendothelial migration of lymphocytes (Cosentino-Gomes et al., 2012), here, we tested whether arsenite-induced ROS also activated PKC, subsequently increasing eNOS-Thr⁴⁹⁷ phosphorylation. Several PKC isoforms are known to have N-terminal regulatory domain containing zinc-binding, cysteine-rich motif, which is susceptible to oxidation leading to PKC activation. However, under our experimental condition, a variety of PKC isoforms including PKCα are unlikely to be activated by arsenite-induced ROS, and therefore PKC may not participate in arsenite-induced decrease in NO production.

In contrast with PKC, our data showed clearly that PP1 activity is involved in arsenite-induced increase in eNOS-Thr⁴⁹⁷ phosphorylation. It was reported that treatment with H₂O₂ led to inactivation of PP1 in human fibroblasts that was reversed by thiol-specific reagents such as dithiothreitol and NAC (Kim et al., 2003), suggesting a role for cysteine oxidation by ROS in the inactivation of PP1. Like human fibroblasts, we also found in BAEC that NAC almost completely recovered decreased PP1 activity by chronic exposure of arsenite, indicating that ROS are upstream molecules of PP1. Disulfide bond formation of PP1 is suggested to be a likely mechanism of PP1 inhibition by ROS because PP1 contains disulfide oxidoreductase active sites (Fetrow et al., 1999). Although ROS-derived decreased PP1 activity mediates arsenite-stimulated increase in eNOS-Thr⁴⁹⁷ phosphorylation, whether decreased PP1 activity directly plays a role in increasing eNOS-Thr⁴⁹⁷ phosphorylation needs further study. Previously, it was reported that senescence-associated ERK phosphorylation and prolonged PKA signal induced by mild oxidation are attributable to ROS-dependent oxidative inactivation of PP1 and PP2A (Kim et al., 2003). Therefore, it is also interesting to identify whether ERK or PKA is able to play a role in connecting PP1 to eNOS-Thr⁴⁹⁷ phosphorylation in pathway responsible for arsenic-stimulated decreases in NO production and vascular function.

In conclusion, arsenite acutely increased eNOS-Thr⁴⁹⁷ phosphorylation, thereby decreasing NO production; this process is mediated by ROS-dependent reduction of PP1 activity. Our results shed light on the molecular mechanisms underlying arsenic-induced eNOS dysregulation associated with disruption of vascular integrity and subsequent development of vascular diseases. Furthermore, based on our results, care should be also exercised even when acutely exposed to arsenite.

**ACKNOWLEDGMENTS**

This work was carried out with the support of "Cooperative Research Program (Risk assessment research in livestock on
exposure to biological, chemical and environmental hazard substance. PJ01052302 for Agriculture Science & Technology Development, Rural Development Administration, Republic of Korea

CONFLICT OF INTEREST

The authors declare that they have no competing interests

REFERENCES


Seo et al. Acute Effect of Arsenite on NO Production
